100% of patients with a single 240 mg dose had complete response at week 8. Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

Wedbush lowered the firm’s price target on Blueprint Medicines (BPMC) to $124 from $135 and keeps an Outperform rating on the shares. The firm ...

A recent population-based study from South Korea highlights the long-term dermatological complications linked to COVID-19 ...

Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...

Despite the promising clinical data, the over 40% drop in Jasper's stock price indicates that investors may have reservations about the study results or the company's future prospects. As the market ...

Despite positive preliminary data from its early stage study of treating hives, Jasper Therapeutics Inc. saw its stock drop dramatically on Jan. 8. Results were from the ongoing phase Ib/IIa study of ...

Urgent care is a walk-in service where you can get testing and treatment for many injuries and illnesses. You can get medical ...

INF-904 is under clinical development by InflaRx and currently in Phase I for Chronic Urticaria Or Hives. According to GlobalData, Phase I drugs for Chronic Urticaria Or Hives have an 87% phase ...

Omalizumab biosimilar is under clinical development by Mabpharm and currently in Phase III for Chronic Urticaria Or Hives.